Publication Date

2013

Abstract

We examined the risk of stroke or systemic embolism (SSE) conferred by heart failure (HF) and left ventricular systolic dysfunction (LVSD) in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation Trial (ARISTOTLE), as well as the effect of apixaban versus warfarin.

School/Institute

Mary MacKillop Institute for Health Research

Document Type

Journal Article

Access Rights

ERA Access

Access may be restricted.

Share

COinS